3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
3
Solid Tumors
2
Hypoxia
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Gastrointestinal Stromal Tumors
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Temozolomide
6
Cyclophosphamide
5
Filgrastim
3
Automobiles
3
sargramostim
2
fludarabine
2
Thalidomide
2
Magnetic Resonance Spectroscopy
2
Etoposide
2
Carmustine
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
thymoglobulin
1
temsirolimus
1
sonidegib
1
ribociclib
1
reolysin
1
pegfilgrastim
1
ibrutinib
1
fludarabine phosphate
1
entinostat
1
carboxyamido-triazole
1
azurin (50-77)
1
aldesleukin
1
Zoledronic Acid
1
Vincristine
1
Verteporfin
1
Valproic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroectodermal Tumors, Primitive
×
TH 302
×
Clear all
NCT01381822
2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1
Unknown
58 enrolled